Study treatment
DISEASE
Eligible patients were randomly assigned (1:1) to the experimental S + XP arm or control XP arm. Randomization was conducted via a computer‐generated random‐block permutation method with stratification factors including countries (Korea vs. China vs. Taiwan), disease status (initially metastatic vs. recurrent), and prior adjuvant chemotherapy (yes vs. no).XP chemotherapy in both groups was given every 3 weeks up to 8 cycles. Patients in the S + XP arm received oral sorafenib 400 mg bid daily, oral capecitabine 800 mg/m